Top

Published in:

01-02-2017 | Original Article

Safety and efficacy of high-rate cutoff and long detection interval ICD programming in secondary prevention patients

Authors: Yusuke Hayashi, Masahiko Takagi, Jun Kakihara, Shogo Sakamoto, Atsushi Doi, Kenichi Sugioka, Akihisa Hanatani, Minoru Yoshiyama

Published in: Heart and Vessels | Issue 2/2017

Abstract

Several trials demonstrated that a long detection interval and a high-rate cutoff reduced implantable cardioverter-defibrillator (ICD) therapy in primary prevention patients. However, only a few data are available for secondary prevention (SP) patients. The aim of this study was to evaluate whether these ICD programming would be effective in reducing ICD therapies in SP patients. We enrolled 65 SP patients under ICD or cardiac resynchronization therapy with the defibrillator programmed with the same setting (conventional setting). During follow-up, we changed detection rates in each zone; cycle length (CL) ≤400 to ≤370 ms for ventricular tachycardia (VT) zone, CL ≤350 to ≤320 ms for fast VT zone, CL ≤300 to ≤270 ms for ventricular fibrillation (VF) zone, and number of intervals to detect ventricular tachyarrhythmia in VF zone: 12–24. We retrospectively compared the incidences of ICD therapies, syncope, and hospitalization due to slow VT under the detection rate between both settings. Median follow-up periods were 5.0 (interquartile range 2.5–7.8) and 2.5 years (interquartile range 2.3–2.7) in conventional and strategic settings, respectively. The incidence of appropriate ATP and shock significantly decreased in strategic setting (conventional and strategic settings: 21.2 and 4.8 ATPs per year, respectively, OR 0.18, 95 % CI 0.06–0.54, p = 0.002, 26.1 and 7.8 shocks per year, respectively, OR 0.29, 95 % CI 0.09–0.88, p = 0.03). The incidence of overall inappropriate therapy significantly decreased (conventional and strategic settings: 17.6 and 2.8 therapies per year, respectively, OR 0.14, 95 % CI 0.05–0.44, p = 0.01). The incidence of syncope and slow VT was not significantly different between both settings. In conclusion, ICD programming-combined long detection interval with high-rate cutoff was effective in reducing appropriate shock and inappropriate therapy without increasing the incidence of syncope and slow VT in SP patients.

Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877–883CrossRefPubMed

Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225–237CrossRefPubMed

The antiarrhythmics versus implantable defebrillators investigators (1997) A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 337:1576–1583CrossRef

Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, Yee R, Guarnieri T, Talajic M, Wilber DJ, Fishbein DP, Packer DL, Mark DB, Lee KL, Bardy GH (2008) Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 359:1009–1017CrossRefPubMedPubMedCentral

Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P, Schuger C, Steinberg JS, Higgins SL, Wilber DJ, Klein H, Andrews ML, Hall WJ, Moss AJ (2008) Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 51:1357–1365CrossRefPubMed

Kolb C, Sturmer M, Sick P, Reif S, Davy JM, Molon G, Schwab JO, Mantovani G, Dan D, Lennerz C, Borri-Brunetto A, Babuty D (2014) Reduced risk for inappropriate implantable cardioverter-defibrillator shocks with dual-chamber therapy compared with single-chamber therapy: results of the randomized option study. JACC. Heart fail 2(6):611–619CrossRefPubMed

Knackstedt C, Arndt M, Mischke K, Marx N, Nieman F, Kunert HJ, Schauerte P, Norra C (2014) Depression, psychological distress, and quality of life in patients with cardioverter defibrillator with or without cardiac resynchronization therapy. Heart Vessels 29:364–374CrossRefPubMed

Ruwald AC, Schuger C, Moss AJ, Kutyifa V, Olshansky B, Greenberg H, Cannom DS, Estes NA, Ruwald MH, Huang DT, Klein H, McNitt S, Beck CA, Goldstein R, Brown MW, Kautzner J, Shoda M, Wilber D, Zareba W, Daubert JP (2014) Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). Circ Arrhythm Electrophysiol 7:785–792CrossRefPubMed

Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, Estes NA 3rd, Greenberg H, Hall WJ, Huang DT, Kautzner J, Klein H, McNitt S, Olshansky B, Shoda M, Wilber D, Zareba W (2012) Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 367:2275–2283CrossRefPubMed

10.

Gasparini M, Proclemer A, Klersy C, Kloppe A, Lunati M, Ferrer JB, Hersi A, Gulaj M, Wijfels MC, Santi E, Manotta L, Arenal A (2013) Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA 309:1903–1911CrossRefPubMed

11.

Saeed M, Hanna I, Robotis D, Styperek R, Polosajian L, Khan A, Alonso J, Nabutovsky Y, Neason C (2014) Programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock: results from the PROVIDE study. J Cardiovasc Electrophysiol 25:52–59CrossRefPubMed

12.

Tan VH, Wilton SB, Kuriachan V, Sumner GL, Exner DV (2014) Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol 7:164–170CrossRefPubMed

13.

Kloppe A, Proclemer A, Arenal A, Lunati M, Martinez Ferrer JB, Hersi A, Gulaj M, Wijffels MC, Santi E, Manotta L, Mangoni L, Gasparini M (2014) Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial. Circulation 130:308–314CrossRefPubMed

14.

Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO, Canby RC, Khalighi K, Machado C, Rubenstein DS, Volosin KJ (2004) Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE RX II) trial results. Circulation 110:2591–2596CrossRefPubMed

15.

Wilkoff BL, Hess M, Young J, Abraham WT (2004) Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. J Cardiovasc Electrophysiol 15:1002–1009CrossRefPubMed

16.

Kutyifa V, Daubert JP, Olshansky B, Huang DT, Zhang C, Ruwald AC, McNitt S, Zareba W, Moss AJ, Schuger C (2015) Characterization and predictors of first and subsequent inappropriate ICD therapy by heart rate ranges: result of the MADIT-RIT efficacy analysis. Heart Rhythm 12(9):2030–2037CrossRefPubMed

17.

Sadoul N, Mletzko R, Anselme F, Bowes R, Schols W, Kouakam C, Casteigneau G, Luise R, Iscolo N, Aliot E (2005) Incidence and clinical relevance of slow ventricular tachycardia in implantable cardioverter-defibrillator recipients: an international multicenter prospective study. Circulation 112:946–953CrossRefPubMed

18.

Ruwald MH, Abu-Zeitone A, Jons C, Ruwald AC, McNitt S, Kutyifa V, Zareba W, Moss AJ (2013) Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy). J Am Coll Cardiol 62:1343–1350CrossRefPubMed

19.

Lee CH, Nam GB, Park HG, Kim HY, Park KM, Kim J, Choi KJ, Kim YH (2008) Effects of antiarrhythmic drugs on inappropriate shocks in patients with implantable cardioverter defibrillators. Circ J 72:102–105CrossRefPubMed

20.

Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe K, Champagne J, Talajic M, Coutu B, Gronefeld GC, Hohnloser SH, Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients in Cardioverter Defibrillator Patients (OPTIC) Investigators (2006) Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA 295:165–171CrossRefPubMed

21.

Suzuki A, Yoshida A, Takei A, Fukuzawa K, Kiuchi K, Takami K, Itoh M, Imamura K, Fujiwara R, Nakanishi T, Yamashita S, Matsumoto A, Shimane A, Okajima K, Hirata K (2015) Prophylactic catheter ablation of ventricular tachycardia before cardioverter-defibrillator implantation in patients with non-ischemic cardiomyopathy: clinical outcomes after a single endocardial ablation. Journal of arrhythmia 31:122–129CrossRefPubMedPubMedCentral

22.

Patel D, Hasselblad V, Jackson KP, Pokorney SD, Daubert JP, Al-Khatib SM (2016) Catheter ablation for ventricular tachycardia (VT) in patients with ischemic heart disease: a systematic review and a meta-analysis of randomized controlled trials. J Interv Card Electrophysiol 45:111–117CrossRefPubMed

23.

Miyamoto K, Noda T, Satomi K, Wada M, Nakajima I, Ishibashi K, Okamura H, Noguchi T, Anzai T, Yasuda S, Ogawa H, Shimizu W, Aiba T, Kamakura S, Kusano K (2015) Larger low voltage zone in endocardial unipolar map compared with that in epicardial bipolar map indicates difficulty in eliminating ventricular tachycardia by catheter ablation. Heart Vessels. doi:10.1007/s00380-015-0732-7

24.

Yokoshiki H, Mitsuyama H, Watanabe M, Mizukami K, Tsutsui H (2014) Suppression of ventricular fibrillation by electrical modification of the purkinje system in hypertrophic cardiomyopathy. Heart Vessels 29:709–717CrossRefPubMed

Title: Safety and efficacy of high-rate cutoff and long detection interval ICD programming in secondary prevention patients
Authors: Yusuke Hayashi
Masahiko Takagi
Jun Kakihara
Shogo Sakamoto
Atsushi Doi
Kenichi Sugioka
Akihisa Hanatani
Minoru Yoshiyama
Publication date: 01-02-2017
Publisher: Springer Japan
Published in: Heart and Vessels / Issue 2/2017
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-016-0850-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Safety and efficacy of high-rate cutoff and long detection interval ICD programming in secondary prevention patients

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2017

Serum carboxy-terminal telopeptide of type I collagen (I-CTP) is predictive of clinical outcome in peripheral artery disease patients following endovascular therapy

Ibutilide protects against cardiomyocytes injury via inhibiting endoplasmic reticulum and mitochondrial stress pathways

Hyponatremia at discharge as a predictor of 12-month clinical outcomes in hospital survivors after acute myocardial infarction

Interventricular dyssynchrony in a patient with a biventricular physiology and a systemic right ventricle

Assessing utility of exercise test in determining exercise prescription in adolescent and adult patients with repaired tetralogy of fallot

Factors associated with postoperative requirement of renal replacement therapy following off-pump coronary bypass surgery